Eli Lilly to test weight loss drugs
Eli Lilly’s Zepbound has outperformed Novo Nordisk’s Wegovy in a recent clinical trial, with patients losing more weight on ...
For a drug that has been on the market for only a year, Eli Lilly and Co.’s anti-obesity treatment Zepbound has quickly made a huge name for itself, racking up more than $3 billion in sales and ...
Shares of Eli Lilly climbed Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo ...
Eli Lilly said its obesity drug Zepbound led to more weight loss than its main rival, Novo Nordisk's Wegovy, in the first head-to-head clinical trial on the two weekly injections. The findings ...
Eli Lilly said its weight loss drug Zepbound led to 47% greater weight reduction than rival medicine Wegovy, made by Novo Nordisk, in a head-to-head randomized controlled trial. The result ...
Per a news release, Eli Lilly's Zepbound is more effective than Novo Nordisk's Wegovy The weight-loss drug market is about to get even more crowded. Eli Lilly & Co (NYSE:LLY) stock is up 2 ...
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than Wegovy, a drug with the main active ingredient semaglutide, according ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback